iPLA2β Overexpression in Smooth Muscle Exacerbates Angiotensin II-Induced Hypertension and Vascular Remodeling

Lindsay E Calderon  
*University of Kentucky*

Shu Liu  
*University of Kentucky*, shu.liu@uky.edu

Wen Su  
*University of Kentucky*, wen.su@uky.edu

Zhongwen Xie  
*University of Kentucky*, zhongwenxie@uky.edu

Zhenheng Guo  
*University of Kentucky*, zguo2@uky.edu

*See next page for additional authors*

Follow this and additional works at: [https://uknowledge.uky.edu/physiology_facpub](https://uknowledge.uky.edu/physiology_facpub)

Part of the Physiology Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Repository Citation  
Calderon, Lindsay E; Liu, Shu; Su, Wen; Xie, Zhongwen; Guo, Zhenheng; Eberhard, Wanda; and Gong, Ming C., "iPLA2β Overexpression in Smooth Muscle Exacerbates Angiotensin II-Induced Hypertension and Vascular Remodeling" (2012). *Physiology Faculty Publications*. 1.  
[https://uknowledge.uky.edu/physiology_facpub/1](https://uknowledge.uky.edu/physiology_facpub/1)

This Article is brought to you for free and open access by the Physiology at UKnowledge. It has been accepted for inclusion in Physiology Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
iPLA2β Overexpression in Smooth Muscle Exacerbates Angiotensin II-Induced Hypertension and Vascular Remodeling

Digital Object Identifier (DOI)
http://dx.doi.org/10.1371/journal.pone.0031850

Notes/Citation Information

© 2012 Calderon et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Authors
Lindsay E Calderon, Shu Liu, Wen Su, Zhongwen Xie, Zhenheng Guo, Wanda Eberhard, and Ming C. Gong

This article is available at UKnowledge: https://uknowledge.uky.edu/physiology_facpub/1
iPLA₂β Overexpression in Smooth Muscle Exacerbates Angiotensin II-Induced Hypertension and Vascular Remodeling

Lindsay E. Calderon¹, Shu Liu³, Wen Su³, Zhongwen Xie², Zhenheng Guo⁴, Wanda Eberhard², Ming C. Gong²
d
¹ Department of Molecular and Biomedical Pharmacology, University of Kentucky, Lexington, Kentucky, United States of America, ² Department of Physiology, University of Kentucky, Lexington, Kentucky, United States of America, ³ Department of Internal Medicine, University of Kentucky, Lexington, Kentucky, United States of America

Abstract

Objectives: Calcium independent group VIA phospholipase A₂ (iPLA₂β) is up-regulated in vascular smooth muscle cells in some diseases, but whether the up-regulated iPLA₂β affects vascular morphology and blood pressure is unknown. The current study addresses this question by evaluating the basal- and angiotensin II infusion-induced vascular remodeling and hypertension in smooth muscle specific iPLA₂β transgenic (iPLA₂β-Tg) mice.

Method and Results: Blood pressure was monitored by radiotelemetry and vascular remodeling was assessed by morphologic analysis. We found that the angiotensin II-induced increase in diastolic pressure was significantly higher in iPLA₂β-Tg than iPLA₂β-Wt mice, whereas, the basal blood pressure was not significantly different. The media thickness and media:lumen ratio of the mesenteric arteries were significantly increased in angiotensin II-infused iPLA₂β-Tg mice. Analysis revealed no difference in vascular smooth muscle cell proliferation. In contrast, adenovirus-mediated iPLA₂β overexpression in cultured vascular smooth muscle cells promoted angiotensin II-induced [³H]-leucine incorporation, indicating enhanced hypertrophy. Moreover, angiotensin II infusion-induced c-Jun phosphorylation in vascular smooth muscle cells overexpressing iPLA₂β to higher levels, which was abolished by inhibition of 12/15 lipoxgenase. In addition, we found that angiotensin II up-regulated the endogenous iPLA₂β protein in-vitro and in-vivo.

Conclusion: The present study reports that iPLA₂β up-regulation exacerbates angiotensin II-induced vascular smooth muscle cell hypertrophy, vascular remodeling and hypertension via the 12/15 lipoxgenase and c-Jun pathways.


Editor: Gangjian Qin, Northwestern University, United States of America

Received October 19, 2011; Accepted January 13, 2012; Published February 20, 2012

Copyright: © 2012 Calderon et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by National Institute of Health (NIH) grants HL-082791 to M.C.G. and HL-088389 to Z.G. L.E.C. was supported by an American Heart Association (AHA) Fellowship-09PRE2300152 and a National Institute of Health (NIH) T32-HL072743. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: mcgong2@uky.edu

Introduction

Phospholipase A₂ is a large family of enzymes that catalyze the hydrolysis of the sn-2 ester bond on phospholipids to produce free fatty acids (e.g., arachidonic acid) and lysophospholipids [1]. Calcium independent group VIA phospholipase A₂ (iPLA₂β), a member of the phospholipase A₂ superfamily, is an intracellular protein that is catalytically active in the absence of calcium [1]. iPLA₂β was initially implicated as a housekeeping enzyme in phospholipid remodeling; however, accumulating evidence indicates that it also plays fundamental roles in cellular signaling, causing cell activation, proliferation, migration or apoptosis [1]. Moreover, iPLA₂β plays a significant role in a variety of diseases including neurodegenerative disorders [2,3], cardiac ischemia induced arrhythmia [4,5,6] and tumor genesis and metastasis [7,8]. However, whether iPLA₂β is involved in hypertension remains unreported.

An estimated 29% of the United States adult (>18 years of age) population is hypertensive, exposing these individuals to an increased risk of mortality and cardiovascular events over their lifespan [9]. The mechanisms underlying primary hypertension remain incompletely understood. Evidence obtained from studies on cultured cells or isolated tissues demonstrate that iPLA₂β is involved in the regulation of multiple vascular smooth muscle functions and thus may contribute to hypertension and associated vascular remodeling. We [10,11] and others [12,13,14] have demonstrated that iPLA₂β plays an important role in vascular smooth muscle contraction regulation. Inhibition of iPLA₂β by the selective suicidal iPLA₂ inhibitor BEL, anti-sense oligonucleotides or genetic deletion drastically inhibit arachidonic acid release induced by vasopressin [15], thrombin [16], and thapsigargin/A23187 [17]. Moreover, inhibition or genetic deletion of iPLA₂β significantly reduce thrombin-induced DNA synthesis [16] and smooth muscle migration and proliferation, which was analyzed in isolated mesentery artery tissue in an explant assay [17], suggesting that iPLA₂β is involved in smooth muscle migration and proliferation. Together, these data imply that vascular smooth muscle iPLA₂β is prohypertensive. On the other hand, iPLA₂β is also required for angiotensin II (Ang II) induced RGS2 transcription in vascular smooth muscle cells (VSMC) [18] and deleting iPLA₂β promotes vascular constriction [14]. Since RGS2 is a negative regulator of Ang
II-induced hypertension, these imply vascular smooth muscle iPLA2β can also be anti-hypertensive. Taken together, the precise role that vascular smooth muscle iPLA2β plays in hypertension and vascular remodeling in vivo remains to be determined.

The activity of iPLA2β is regulated at multiple levels including allosteric interaction with ATP [19] or calmodulin [20], covalent modification by acylation [21], and potentially by proteolysis and translocation [22]. Interestingly, recent evidence suggests that, in addition to post-translational regulation, the iPLA2β protein level is up-regulated under various pathological conditions; the mRNA and protein are up-regulated in Type 1 diabetic Akita mouse pancreatic cells [23], in astrocytes stimulated with pro-inflammatory lipoxygenase-modified arachidonic acid and Indomethacin were purchased from Biomol (Plymouth Meeting, PA). The primary antibodies to β-actin, phospho-c-Jun, phospho-p38 MAPK, total-p38 MAPK were purchased from Cell Signaling (Danvers, MA). The iPLA2β antibody was made in our lab, and the generation and characterization of the antibody was previously documented [16].

Primary Cell Culture

Aortic VSMC were isolated from 12–13 wk old rats or mice and used at passages 5 to 10 as previously described [25].

Western Blot

After the indicated treatments, cells were collected, lysates were prepared, and the proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose membranes, which were then western blotted with the following antibodies: iPLA2β (1:2500), β-actin (1:2500), phospho-c-Jun (1:1000), phospho-p38 MAPK (1:2000), total-p38 MAPK (1:2000), respectively. The proteins were quantified using the ECL Plus Western Blotting Detection System (GE Healthcare).

Blood Pressure Measurement

Eight pairs of 13-wk old male iPLA2β-Tg and iPLA2β-Wt (littermate) mice were anesthetized with isoflurane and implanted with telemetry probes (TA11PA-C10, Data Sciences International, St. Paul, MN) in the left carotid artery. After 7 to 10 days of recovery, basal blood pressure, heart rate, and locomotor activity data were collected continuously using the Dataquest A.R.T. system (Data Sciences International, St. Paul, MN) for 72 h. Osmotic mini-pumps (Alzet Model 2002) were then implanted, subcutaneously, to infuse Ang II (500 ng/kg/min, 14 days) or saline. During the infusion period, blood pressure data was collected continuously for 24 h every other day.

Morphometric Analysis of Vascular Remodeling

At the 14th day of Ang II or saline infusion, the mice were euthanized and perfused under physiological pressure with PBS and 4% paraformaldehyde. Thoracic aortas (2 mm from descending aorta) and secondary branches of the mesenteric arteries were isolated, cleaned, embedded, and cut into 5 μm sections. Sections were stained with HE (Hematoxylin-Eosin, Surgipath), or Elastin (Elastin Stain kit, Richard-Allan Scientific), or collagen (Masson Trichrome Stain, Richard-Allan Scientific). Images were captured and analyzed using an Olympus digital camera with Olympus MicroSuit-B3 Software. Elastin stained slides were used for morphometric analysis. The media thickness was determined by measuring the distance from the internal elastic lamina (IEL) to the external elastic lamina (EEL). For each slide, measurements from 4 points (12, 3, 6 and 9 o’clock positions) were averaged. The media area was determined by measuring the area between the IEL and EEL. The medial/lumen ratio was calculated based on the measured lumen area and media areas.

Immunohistochemistry

Slides with paraffin embedded vascular sections were antigen retrieved (Low pH antigen retrieve buffer, Vector laboratory), and then treated with 3% hydrogen peroxide for 20 min to quench the endogenous peroxidases. After blocking the endogenous biotin (Avidin/Biotin blocking kit, Vector Laboratory), the slides were blocked with normal goat serum (Vectastain ABC Kit) for 1 h and were incubated overnight at 4°C with anti-iPLA2β (1:5000) or anti-Proliferating Cell Nuclear Antigen antibody (PCNA, Cell signaling technology). The slides were then incubated with secondary antibodies, washed, incubated with the Avidin-Biotin-Peroxidase complex (Vector Laboratories) for 30 min, washed, and stained with DAB (DAKO) and counter stained with hematoxylin (Surgipath). Images were taken using an Olympus 1×70 microscope.

OCT embedded 2nd order mesentery artery branches were sectioned and fixed for 30 min in paraformaldehyde. Sections were blocked with normal goat serum and incubated with anti-iPLA2β (1:100). Slides were then washed, incubated in fluorescently-labeled (1:200, Alexa-Fluor 594, Invitrogen) secondary antibodies and counterstained with DAPI (300 nM).
iPLA₂β Adenoviral Infection

The doxycycline-inducible iPLA₂β-expressing adenoviral vectors were generated and purified as previously described [10]. Serum starved cells were infected for 12 h with Ad-iPLA₂β (500 MOI) and Ad-Tet-on (2000 MOI). Doxycyclin (1 mg/ml) was added to the culture medium for 24 h to induce iPLA₂β expression. The cells were then harvested for iPLA₂β protein expression analysis or used for [3H]-leucine incorporation assay.

[3H]-Leucine Incorporation

After the indicated treatment, the VSMC were incubated with [3H]-leucine (0.25 μCi/well) for 24 h, washed, harvested and [3H]-leucine incorporation was quantified by liquid scintillation spectroscopy (Packard, Packard BioScience Company) as previously described [26].

Statistical Analysis

Each experiment was repeated a minimum of three times. Data were expressed as mean ± S.E. Statistical analysis was performed by using one- and/or two-way analysis of variance with repeated measurement for multiple groups. A post-hoc Bonferroni analysis was performed when appropriate (GraphPad Prism 4). Statistical significance was set at p<0.05.

Results

Smooth muscle specific iPLA₂β overexpression exacerbates Ang II infusion-induced hypertension without affecting basal blood pressure

To examine the role of iPLA₂β in basal blood pressure and in Ang II-induced hypertension, we utilized the smooth muscle specific iPLA₂β-Tg mice that we previously developed (Liu et al., manuscript submitted). No significant difference was detected in basal systolic (Fig. 1A); diastolic (Fig. 1B) or mean arterial blood pressure (Fig. 1C) between the iPLA₂β-Tg and iPLA₂β-Wt mice. Ang II infusion (500 ng/kg/min, 14 days) rapidly increased systolic, diastolic, and mean arterial pressure in both strains (Fig. 1A–C); saline infusion did not affect these parameters (Data not shown). Interestingly, diastolic pressure after Ang II infusion was significantly higher in iPLA₂β-Tg mice (115±8.6 mmHg) than in the iPLA₂β-Wt mice (107±10.3 mmHg) (Fig. 1B). Both the systolic and mean arterial pressures were higher in the iPLA₂β-Tg mice after Ang II infusion, but the difference did not reach statistical significance. Additionally, no difference in the heart rate or pulse pressure was detected and the locomotor activity was lower in the iPLA₂β-Tg mice than the iPLA₂β-Wt mice (Fig. 1D–F).

Vascular remodeling induced by Ang II infusion is exacerbated in iPLA2-Tg mice

To investigate the mechanism underlying the exacerbation of Ang II infusion-induced blood pressure elevation in iPLA₂β-Tg mice, we used morphometric analysis to determine whether iPLA₂β overexpression affects Ang II-induced vascular remodeling. In the mesenteric arteries, iPLA₂β overexpression did not significantly alter mesenteric artery collagen or elastin expression (Fig. 2A). However, iPLA₂β overexpression significantly promoted the Ang II infusion-induced increase in media thickness (Fig. 2B) and media: luminal ratio (Fig. 2C). In the thoracic aorta, iPLA₂β overexpression also significantly promoted Ang II infusion-induced increases in media thickness (Fig. 3B) without altering the mediolumen ratio (Fig. 3C) and the elastin or collagen expression (Fig. 3A).

iPLA₂β overexpression enhances Ang II-induced vascular remodeling by promoting vascular smooth muscle hypertrophy via the 12/15 lipoxygenase pathway

To elucidate the mechanism via which iPLA₂β enhances Ang II-induced vascular remodeling, we investigated the effects of iPLA₂β overexpression on VSMC proliferation and hypertrophy.
The proliferation state was assessed by PCNA staining and cell counting. No significant difference was detected in PCNA staining [aorta (Fig. 4A) or mesentery artery (data not shown)] or cell number [aorta and mesentery artery (Fig. 4B,C)].

Next, we examined the effect of iPLA2β overexpression on Ang II-induced vascular smooth muscle hypertrophy in cultured VSMC. We found that exogenous overexpressed iPLA2β was gradually lost during the passage of VSMC isolated from the iPLA2β-Tg mice; therefore, we overexpressed iPLA2β by doxycycline inducible adenoviral vector mediated gene transfer as previously described [11,18] and achieved an 11-fold increase in iPLA2β protein expression (data not shown). Ang II-induced [3H]-leucine incorporation was significantly enhanced by iPLA2β overexpression to 1.73-fold (Fig. 5A). As a control, neither doxycycline nor adenovirus treatment alone had an effect on the basal [3H]-leucine incorporation (Fig. 5A). Together, these results suggest that iPLA2β overexpression facilitates VSMC hypertrophy.

To dissect the mechanism downstream of iPLA2β that exacerbates Ang II-induced VSMC hypertrophy, we examined the role of the arachidonic acid metabolites from lipoxygenase, cyclooxygenase or P450 pathways on [3H]-leucine incorporation. The inhibition of lipoxygenase by NDGA nearly abolished both basal and Ang II-induced [3H]-leucine incorporation (Fig. 5B), whereas, inhibition of cyclooxygenase by Indomethacin had no effect. P450 inhibition by ODA significantly attenuated Ang II-stimulated [3H]-leucine incorporation (Fig. 5B). VSMC isolated from 12/15 lipoxygenase knockout (lox2/2) mice also showed a significant attenuation of Ang II stimulated [3H]-leucine incorpo-
ration (Fig. 5C), verifying the essential role of iPLA2β and the 12/15 lipoxygenase pathway in Ang II-induced VSMC hypertrophy. iPLA2β overexpression promotes Ang II-induced c-Jun phosphorylation via the 12/15 lipoxygenase metabolites c-Jun phosphorylation has been demonstrated to be required for Ang II-induced VSMC hypertrophy. We therefore further investigated whether iPLA2β overexpression exacerbates Ang II-induced c-Jun phosphorylation by immunohistochemistry using mesentery artery sections from iPLA2β-Wt and iPLA2β-Tg mice. Ang II infusion enhanced the staining in both the iPLA2β-Wt and iPLA2β-Tg mouse sections (Fig. 6A). Moreover, the staining in the iPLA2β-Tg mice was much higher than that in the iPLA2β-Wt mice (Fig. 6A), indicating that iPLA2β overexpression promotes Ang II infusion-induced c-Jun phosphorylation.

To further clarify the mechanism downstream of iPLA2β, we examined the role of the arachidonic acid metabolites in Ang II-induced c-Jun phosphorylation. The results demonstrate that inhibition of lipoxygenase by NDGA, but not inhibition of cyclooxygenase by indomethacin or P450 by ODA significantly attenuated Ang II-induced c-Jun phosphorylation (Fig. 6B, C). A significant attenuation of Ang II-stimulated c-Jun phosphorylation was also observed in VSMC isolated from 12/15 lipoxygenase knockout (lox−/−) mice (Fig. 6D, E), indicating a critical role of the 12/15 lipoxygenase pathway in Ang II-induced VSMC hypertrophy. Interestingly, the Ang II-induced p38 MAPK

---

**Figure 3. Exacerbated thoracic aorta remodeling in iPLA2β-Tg mice in response to Ang II infusion.** Vascular remodeling was analyzed in the thoracic aorta of the iPLA2β-Wt and iPLA2β-Tg infused with Ang II (500 ng/kg/min) or saline. Representative images of vessel sections stained with HE, elastin or collagen (A). The media thickness (B) and media:lumen ratio (C) were quantified. n = 8, **: p < 0.01, ***: p < 0.001 by one way ANOVA. doi:10.1371/journal.pone.0031850.g003
phosphorylation was not affected by any of the arachidonic acid metabolism enzyme inhibitors tested (Fig. 7A, B).

Ang II increases endogenous iPLA₂β protein expression in VSMC

To further explore a possible role of endogenous iPLA₂β in Ang II's effects, we determined whether iPLA₂β protein is up-regulated by Ang II in-vitro and in-vivo. In cultured iPLA₂β-Wt VSMC, Ang II treatment significantly increased iPLA₂β protein expression within the time frame from 3 h to 48 h (Fig. 8A–B). In-vivo, Ang II infusion enhanced iPLA₂β protein expression in the thoracic aorta as indicated by immunohistochemical analysis (Fig. 8C, note brown color accumulation in the media layer).

Discussion

In the present study, we investigate the role of up-regulated smooth muscle iPLA₂β in Ang II-induced VSMC hypertrophy, vascular remodeling and hypertension. Several novel findings are reported here. First, using a smooth muscle specific iPLA₂β-Tg mouse model, we find that overexpression of iPLA₂β in smooth muscle exacerbates Ang II infusion-induced blood pressure...
Figure 6. iPLA2β overexpression promotes Ang II-induced c-Jun phosphorylation via the 12/15 lipoxygenase pathway. (A) iPLA2β-Wt and iPLA2β-Tg mice were infused with Ang II (1000 ng/kg/min, 14 days) or saline and 2nd order branch of mesenteric arteries VSMC were isolated and embedded in OCT. Vessel sections were stained with anti-p-c-Jun antibody and DAPI. (B) and (D) are representative western blots, (C) and (E) are quantifications of the blots, of c-Jun phosphorylation in aortic VSMCs after the same treatments as in Fig. 3 B and C. n = 3–4, *p<0.05, **: p<0.01, ***: p<0.001 one-way ANOVA.

doi:10.1371/journal.pone.0031850.g006
increase and vessel remodeling. Second, we demonstrate that the up-regulated iPLA2β acts via the 12/15 lipoxygenase pathway to induce c-Jun phosphorylation and to promote Ang II-induced VSMC hypertrophy. Third, Ang II up-regulates iPLA2β protein in cultured VSMCs and in vivo during Ang II-infusion.

Metabolites of free arachidonic acid produced by the three major pathways, cyclooxygenase [27,28], lipoxygenase [29,30] and cytochrome P450 [31] have been demonstrated to play a role in hypertension. Different classes of phospholipase A2 may be responsible for the release of arachidonic acid, which is rate-limiting. Among these phospholipases, the cytosolic calcium-dependent cPLA2 has been shown to play an important role in the development of hypertension induced by chronic NO inhibition [32]. However, to the best of our knowledge, whether the cytosolic calcium-independent phospholipase A2, iPLA2β, participates in hypertension has not been reported. The current study for the first time demonstrates that iPLA2β overexpression in smooth muscle does not alter basal blood pressure, but exacerbates Ang II infusion-induced hypertension and vascular remodeling. The lack of effect on basal blood pressure by iPLA2β overexpression is likely due to the fact that under resting conditions iPLA2β is presumably bound to calmodulin thus catalytically inactive [13]. Upon Ang II stimulation, iPLA2β is dissociated from calmodulin and activated therefore exacerbating Ang II infusion-induced blood pressure increase. Several lines of evidence suggest that the enhanced Ang II infusion-induced blood pressure increase is specifically caused by iPLA2β overexpression in vascular smooth muscle. First, the locomotor activity nor heart rate is increased in the iPLA2β-Tg mice (Fig. 1D, F), suggesting that locomotor activity and heart rate are not responsible for the exaggerated increase in blood pressure in response to Ang II-infusion. Second, among the diastolic, systolic and mean arterial pressure, the diastolic pressure exhibited the most enhancement by iPLA2β overexpression [Fig. 1]. It is established that enhanced diastolic pressure is associated with an increase in peripheral resistance, whereas, enhanced systolic pressure is reliant on an increase in large conduit vessel stiffness and stroke volume [33]. The selective diastolic pressure enhancement observed in iPLA2β-Tg mice, in response to Ang II infusion, suggests that it is the increase in resistance of the vasculature that accounts for the enhanced blood pressure response. Third, morphometric analysis of the mesentery arteries reveals that the media thickness and media:lumen ratio are significantly increased in the iPLA2β-Tg mice [Fig. 1]. This enhanced vessel remodeling in small arteries is expected to increase peripheral resistance and thus contributes to the enhanced diastolic blood pressure observed in the iPLA2β-Tg mice. Finally, the systolic blood pressure was similar in the iPLA2β-Tg and control mice. This is consistent with the observation that there was no significant difference in the aorta elastin and collagen content, which implies that the stiffness of the conduit vessels is similar in the iPLA2β-Tg and iPLA2β-Wt mice.

Phospholipase A2 and arachidonic acid metabolites are involved in hypertension caused by various mechanisms; however, it is interesting to note that blood pressure under basal physiological

Figure 7. Lack of effects of inhibiting arachidonic acid metabolism on Ang II induced p38 MAPK activation. VSMC were isolated from the aortas of iPLA2β-Wt mice and incubated with inhibitors of lipoxygenase (NDGA, 30 µM), cyclooxygenase (Indomethacin, 50 µM) or P450 cytochrome C (ODA, 10 µM) and stimulated with Ang II (100 nM) or saline for 1 h. Then the total- or phosphorylated p38 MAPK was determined by Western Blot. n = 3–4. doi:10.1371/journal.pone.0031850.g007

Figure 8. Ang II enhances iPLA2β protein expression in cultured VSMC and in vivo. 24 h serum-deprived rat aortic VSMC were stimulated with Ang II (100 nM) for various time intervals as indicated. iPLA2β protein abundance was determined by Western Blot (A and B). Representative immunohistochemical images of iPLA2β protein staining in C57/B6 thoracic aorta from iPLA2β-Wt and iPLA2β-Tg mice infused with saline or Ang II (500 ng/kg/min, 14 days) (C). n = 4–5; *: p<0.05 by one-way ANOVA analysis. doi:10.1371/journal.pone.0031850.g008
conditions was not affected by iPLA2b smooth muscle overexpression [present study], or by deleting cPLA2 [34] or 12/15 lipoygenase [30]. This suggests that the arachidonic acid metabolites do not alter basal blood pressure homeostasis, but play a significant role in pathological hypertension induced by Ang II infusion (present study), renal artery occlusion, or blockade of NO [30,35]. These observations raise the possibility that the phospholipase A2/arachidonic acid pathway is a therapeutic target for selective lowering of blood pressure under pathological conditions without disturbing normal physiological blood pressure.

The exacerbation of vascular remodeling in iPLA2b-Tg mice can be a consequence in response to increased blood pressure or an enhancement of Ang II's direct effect on vasculature. In cultured VSMC, we found that iPLA2b overexpression enhanced Ang II-induced [3H]-leucine incorporation, indicating promotion of Ang II's direct effects on VSMC account for, at least in part, the exacerbation of vascular remodeling. Increased VSMC proliferation and/or hypertrophy may underlie the enhanced vascular remodeling. Our results demonstrate selectively enhanced hypertrophy in the absence of detectable alterations of proliferation in both mesenteric arteries and descending aortas in iPLA2b-Tg mice. This further suggests that iPLA2b overexpression amplifies Ang II mediated hypertrophic pathways and is consistent with the observations of others who found that Ang II selectively induces hypertrophy in cultured VSMCs [36] and in-vivo in the descending aorta [37].

Among the elaborate signaling network activated by Ang II, the lipoygenase [38], c-Jun NH2-terminal kinase [JNK] [39] and p38 MAPK [40] pathways are known to be essential mediators of Ang II induced VSMC hypertrophy. This study demonstrates that iPLA2b overexpression potentiates Ang II induced VSMC hypertrophy via activation of the lipoygenase pathway since [3H]-leucine incorporation was inhibited by NDGA (Fig. 5B) or by genetic deletion of 12/15 lipoygenase (Fig. 5C). Interestingly, only the JNK activation, as indicated by increased c-Jun phosphorylation (Fig. 6B-E), but not p38 MAPK (Fig. 7A,B) is affected by inhibition of the 12/15 lipoygenase pathway. This is consistent with the report that p38 MAPK is upstream of and required for iPLA2b activation induced by thrombin [16].

In addition to iPLA2b, cPLA2 has been shown to be activated by Ang II [41,42] and is required for Ang II-induced arachidonic acid release [43] and hypertrophy [44] in VSMC. The relationship between the cPLA2 and iPLA2b in the regulation of arachidonic acid release and cell hypertrophy remain to be established. It is conceivable that iPLA2b and cPLA2 act in a sequential manner. iPLA2b has been demonstrated to play a critical role in store-operated calcium influx [45] and that is crucial for cPLA2b activation [35]. Indeed, iPLA2b has been shown to mediate the early phase whereas cPLA2 mediates the late phase of arachidonic acid release in response to thapsigargin and ionophore A23187 in VSMCs [17].

Emerging evidence suggests that iPLA2b protein level is increased under disease conditions including ischemia [6], Type I diabetes mellitus in pancreatic β-cells [23] and vascular tissues [11], in addition to being regulated by complex post-translational modifications. Whereas, thrombin activation of iPLA2b is not associated with iPLA2b protein level alterations [16], the current study demonstrates that Ang II activation of iPLA2b is associated with up-regulation of iPLA2b protein in cultured VSMC and in-vivo in the vascular tissue (Fig. 8A-C). This is the first evidence that a G-protein-coupled-receptor agonist can up-regulate iPLA2b protein, suggesting that the regulation of iPLA2b protein is agonist specific. However, whether iPLA2b protein up-regulation is required for Ang II infusion induced hypertension requires further investigation using iPLA2b knockout mice.

In summary, the present study is the first to demonstrate a novel role of up-regulated vascular smooth muscle iPLA2b in Ang II-induced hypertension, vascular remodeling and VSMC hypertrophy. This effect of iPLA2b is mediated via the lipoygenase pathway, which induces JNK activation. Ang II stimulation up-regulates iPLA2b protein expression and these results suggest that up-regulated iPLA2b has significant effects on the vasculature.

Acknowledgments

We are grateful to Ming Zhang for her technical assistance and to Wendy Katz at the COBRE research core facility (NIH-COBRE, P20RR021954) for embedding and sectioning vascular samples.

Author Contributions

Conceived and designed the experiments: LC SL WS ZX ZG MG. Performed the experiments: LC SL WS WE. Analyzed the data: LC SL WS ZX WE. Wrote the paper: LC MG.

References


